Aadi Bioscience Inc (AADI)
1.87
+0.03
(+1.63%)
USD |
NASDAQ |
May 09, 16:00
1.87
0.00 (0.00%)
After-Hours: 20:00
Aadi Bioscience Enterprise Value: -62.93M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | -62.93M |
| May 08, 2024 | -63.67M |
| May 07, 2024 | -57.04M |
| May 06, 2024 | -59.74M |
| May 03, 2024 | -56.79M |
| May 02, 2024 | -59.25M |
| May 01, 2024 | -61.21M |
| April 30, 2024 | -61.70M |
| April 29, 2024 | -63.17M |
| April 26, 2024 | -65.88M |
| April 25, 2024 | -67.59M |
| April 24, 2024 | -65.14M |
| April 23, 2024 | -63.67M |
| April 22, 2024 | -62.19M |
| April 19, 2024 | -63.67M |
| April 18, 2024 | -64.65M |
| April 17, 2024 | -64.16M |
| April 16, 2024 | -64.89M |
| April 15, 2024 | -62.19M |
| April 12, 2024 | -60.72M |
| April 11, 2024 | -59.98M |
| April 10, 2024 | -59.74M |
| April 09, 2024 | -57.28M |
| April 08, 2024 | -56.05M |
| April 05, 2024 | -56.54M |
| Date | Value |
|---|---|
| April 04, 2024 | -55.56M |
| April 03, 2024 | -55.07M |
| April 02, 2024 | -55.32M |
| April 01, 2024 | -52.12M |
| March 28, 2024 | -51.39M |
| March 27, 2024 | -50.65M |
| March 26, 2024 | -54.83M |
| March 25, 2024 | -55.56M |
| March 22, 2024 | -55.32M |
| March 21, 2024 | -56.05M |
| March 20, 2024 | -55.07M |
| March 19, 2024 | -56.54M |
| March 18, 2024 | -56.79M |
| March 15, 2024 | -55.56M |
| March 14, 2024 | -58.51M |
| March 13, 2024 | -55.81M |
| March 12, 2024 | -61.21M |
| March 11, 2024 | -56.05M |
| March 08, 2024 | -56.30M |
| March 07, 2024 | -54.33M |
| March 06, 2024 | -55.32M |
| March 05, 2024 | -57.04M |
| March 04, 2024 | -49.06M |
| March 01, 2024 | -61.70M |
| February 29, 2024 | -60.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-71.02M
Minimum
Dec 22 2023
687.27M
Maximum
Sep 22 2021
124.83M
Average
127.87M
Median
Enterprise Value Benchmarks
| Aquestive Therapeutics Inc | 245.19M |
| 89bio Inc | 313.90M |
| NovaBay Pharmaceuticals Inc | 2.645M |
| Palatin Technologies Inc | 28.44M |
| iBio Inc | 16.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.27M |
| Revenue (Quarterly) | 6.326M |
| Total Expenses (Quarterly) | 24.04M |
| EPS Diluted (Quarterly) | -0.60 |
| Gross Profit Margin (Quarterly) | 85.35% |
| Profit Margin (Quarterly) | -257.2% |
| Earnings Yield | -130.5% |
| Normalized Earnings Yield | -130.48 |